"The investigational monoclonal antibody BIIB033 (Biogen) appears not only to improve optic nerve latency in the affected eye of patients with acute optic neuritis (AON), often one of the first manifestations of multiple sclerosis (MS), but also h"...
The most frequently reported ocular event in clinical trials was burning/stinging on instillation and was comparable between Betimol* and timolol maleate (approximately one in eight patients).
The following adverse events were associated with use of Betimol® in frequencies of more than 5% in two controlled, double masked clinical studies in which 184 patients received 0.25% or 0.5% Betimol:
BODY AS A WHOLE: Headache.
The following side effects were reported in frequencies of 1 to 5%:
METABOLIC/NUTRITIONAL: Peripheral edema.
NERVOUS SYSTEM/PSYCHIATRY: Dizziness and dry mouth.
RESPIRATORY: Respiratory infection and sinusitis.
In addition, the following adverse reactions have been reported with ophthalmic use of beta blockers:
BODY AS A WHOLE: Chest pain.
Read the Betimol (timolol ophthalmic solution) Side Effects Center for a complete guide to possible side effects
Beta-adrenergic blocking agents: Patients who are receiving a beta-adrenergic blocking agent orally and Betimol® should be observed for a potential additive effect either on the intraocular pressure or on the known systemic effects of beta-blockade.
Patients should not usually receive two topical ophthalmic beta-adrenergic blocking agents concurrently.
Catecholamine-depleting drugs: Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
Caution should be used in the co-administration of beta-adrenergic blocking agents and oral or intravenous calcium antagonists, because of possible atrioventricular conduction disturbances, left ventricular failure, and hypotension. In patients with impaired cardiac function, co-administration should be avoided.
Digitalis and Calcium Antagonists
The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time.
(See PRECAUTIONS, General, Anaphylaxis.)
Read the Betimol Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 2/22/2016
Additional Betimol Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.